A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label phase I/II study that will investigate the combination of dasatinib and
rituximab therapy in patients with relapsed/refractory CLL. In phase I, eligible subjects
will take either 100 mg or 140 mg of dasatinib daily along with rituximab on day 1 of each
cycle for 6 cycles. In phase II, eligible subjects will all receive the same dose of
dasatinib, as established in the phase I portion, along with rituximab on day 1 of each cycle
for 6 cycles.
The investigators hypothesize that the combination of dasatinib and rituximab will
demonstrate efficacy in the treatment of patients with relapsed/refractory CLL.